Case report: Successful therapy with azacitidine for acute myeloid leukemia with NUP98::RARG resembling acute promyelocytic leukemia

Zhichen Wei; Linlin Shao; Shuqian Xu; Xiaolin Zhang; Lin Wang; Ping Qin; Qiang Song; Ming Hou; Ming Hou; Yan Shi

doi:10.3389/fonc.2024.1460557

Frontiers in Oncology (Sep 2024)

Case report: Successful therapy with azacitidine for acute myeloid leukemia with NUP98::RARG resembling acute promyelocytic leukemia

Zhichen Wei,
Linlin Shao,
Shuqian Xu,
Xiaolin Zhang,
Lin Wang,
Ping Qin,
Qiang Song,
Ming Hou,
Ming Hou,
Yan Shi

Affiliations

Zhichen Wei: Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
Linlin Shao: Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
Shuqian Xu: Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
Xiaolin Zhang: Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
Lin Wang: Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
Ping Qin: Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
Qiang Song: Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
Ming Hou: Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
Ming Hou: Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
Yan Shi: Department of Hematology, Qilu Hospital of Shandong University, Jinan, China

DOI: https://doi.org/10.3389/fonc.2024.1460557
Journal volume & issue: Vol. 14

Abstract

Read online

We report a case of acute myeloid leukemia (AML) with retinoic acid receptor gamma (RARG) rearrangement, exhibiting clinical, morphological, and immunophenotypic features similar to classic acute promyelocytic leukemia (APL). RNA sequencing analysis of the patient’s bone marrow samples revealed the presence of nucleoporin 98 (NUP98)-RARG caused by translocation. AML with RARG rearrangement is insensitive to all-trans retinoic acid (ATRA) and arsenic trioxide. The patient received azacitidine therapy after failing ATRA and standard 3 + 7 therapy (idarubicin and cytarabine) and achieved complete remission. Conclusively, this acute myeloid leukemia subtype may benefit from azacitidine.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords